Therapy of type 1 diabetes with CD4+CD25highCD127-regulatory T cells prolongs survival of pancreatic islets - Results of one year follow-up

Clinical Immunology

Volumn 153, Issue 1, 2014, Pages 23-30

  Marek Trzonkowska, Natalia ^a   Myśliwiec, Małgorzata ^a   Dobyszuk, Anita ^a   Grabowska, Marcelina ^a   Derkowska, Ilona ^a   Juścińska, Jolanta ^b   Owczuk, Radosław ^a   Szadkowska, Agnieszka ^c   Witkowski, Piotr ^d   Młynarski, Wojciech ^c   Jarosz Chobot, Przemysława ^e   Bossowski, Artur ^f   Siebert, Janusz ^a   Trzonkowski, Piotr ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b Regional Center of Blood Donation and Treatment Hoene Wro skiego   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d UNIVERSITY OF CHICAGO   (United States)

^e MEDICAL UNIVERSITY OF SILESIA   (Poland)

^f MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Immunotherapy; Tregs; Type 1 diabetes mellitus

Indexed keywords

C PEPTIDE; CD4 ANTIGEN; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; IMMUNOGLOBULIN G ANTIBODY; INSULIN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; RUBELLA ANTIBODY; RUBELLA VACCINE;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; AUTOTRANSPLANTATION; BLOOD SAMPLING; CELL SURVIVAL; CELL TRANSPLANTATION; CHILD; CHILDHOOD DISEASE; CHRONIC SINUSITIS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; EX VIVO STUDY; FOLLOW UP; GASTROENTERITIS; GLUCOSE BLOOD LEVEL; GOOD MANUFACTURING PRACTICE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; METABOLIC REGULATION; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PATIENT SAFETY; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REMISSION; REPEATED DRUG DOSE; RUBELLA; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE; VACCINATION;

CD4+CD25+ T REGULATORY CELLS; IMMUNOTHERAPY; TREGS; TYPE 1 DIABETES MELLITUS;

ADOLESCENT; C-PEPTIDE; CELL- AND TISSUE-BASED THERAPY; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-7 RECEPTOR ALPHA SUBUNIT; ISLETS OF LANGERHANS TRANSPLANTATION; RISK FACTORS; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 84899144218     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.03.016     Document Type: Article

References (18)

1. Eisenbarth G.S. Type I. diabetes mellitus. A chronic autoimmune disease. N. Engl. J. Med. 1986, 314:1360-1368.
2. Marek-Trzonkowska N., Mysliwiec M., Siebert J., Trzonkowski P. Clinical application of regulatory T cells in type 1 diabetes. Pediatr. Diabetes 2013, 14:322-332.
3. Thomas H.R., Gitelman S.E. Altering the course of type 1 diabetes: an update on prevention and new-onset clinical trials. Pediatr. Diabetes 2013, 14:311-321.
4. Marek-Trzonkowska N., Mysliwiec M., Dobyszuk A., Grabowska M., Techmanska I., Juścińska J., et al. Administration of CD4+CD25highCD127-regulatory T cells preserves β-cell function in type 1 diabetes in children. Diabetes Care 2012, 35:1817-1820.
5. Trzonkowski P., Bieniaszewska M., Juścińska J., Dobyszuk A., Krzystyniak A., Marek N., et al. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin. Immunol. 2009, 133:22-26.
6. Marek N., Bieniaszewska M., Krzystyniak A., Juscinska J., Mysliwska J., Witkowski P., et al. The time is crucial for ex vivo expansion of T regulatory cells for therapy. Cell Transplant. 2011, 11-12:1747-1758.
7. Trzonkowski P., Dukat-Mazurek A., Bieniaszewska M., Marek-Trzonkowska N., Dobyszuk A., Juścińska J., et al. Treatment of graft-versus-host disease with naturally occurring T regulatory cells. BioDrugs 2013, 27:605-614.
8. You S., Slehoffer G., Barriot S., Bach J.F., Chatenoud L. Unique role of CD4+CD62L+regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2004, (Suppl. 2):14580-14585.
9. Diotti R.A., Nakanishi A., Clementi N., Mancini N., Criscuolo E., Solforosi L., et al. JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes?. Clin. Dev. Immunol. 2013, 2013:967581.
10. Herold K.C., Gitelman S.E., Ehlers M.R., Gottlieb P.A., Greenbaum C.J., Hagopian W., et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013, 62:3766-3774.
11. Komatsu N., Mariotti-Ferrandiz M.E., Wang Y., Malissen B., Waldmann H., Hori S. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:1903-1908.
12. Miyao T., Floess S., Setoguchi R., Luche H., Fehling H.J., Waldmann H., Huehn J., Hori S. Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. Immunity 2012, 36:262-275.
13. Zheng S.G. Regulatory T, cells vs Th17: differentiation of Th17 versus Treg, are the mutually exclusive?. Am. J. Clin. Exp. Immunol. 2013, 2:94-106.
14. Trzonkowski P., Debska-Ślizień A., Jankowska M., Wardowska A., Carvalho-Gaspar M., Hak L., et al. Immunosenescence increases the rate of acceptance of kidney allotransplants in elderly recipients through exhaustion of CD4+ T-cells. Mech. Ageing Dev. 2010, 131:96-104.
15. Trzonkowski P., Szmit E., Myśliwska J., Myśliwski A. CD4+CD25+ T regulatory cells inhibit cytotoxic activity of CTL and NK cells in humans-impact of immunosenescence. Clin. Immunol. 2006, 119:307-316.
16. Golab K., Leveson-Gower D., Wang X.J., Grzanka J., Marek-Trzonkowska N., Krzystyniak A., et al. Challenges in cryopreservation of regulatory T cells (Tregs) for clinical therapeutic applications. Int. Immunopharmacol. 2013, 16:371-375.
17. Milward K., Issa F., Hester J., Figueroa-Tentori D., Madrigal A., Wood K.J. Multiple unit pooled umbilical cord blood is a viable source of therapeutic regulatory T cells. Transplantation 2013, 95:85-93.
18. Bluestone J.A. T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs Pubmed Clinical Trials; study no NCT01210664 available at:, (last assessed 01.12.2013). http://www.clinicaltrials.gov.